Somnomed Limited (AU:SOM) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
SomnoMed Limited has undergone significant changes with the appointment of co-CEOs Karen Borg and Amrita Blickstead, who have driven growth and operational improvements. The company reported FY24 revenue of $91.7 million and has focused on strengthening its manufacturing capabilities to meet rising product demand. With recent FDA clearance of its innovative Rest Assure® device, SomnoMed aims for continued growth and improved financial stability.
For further insights into AU:SOM stock, check out TipRanks’ Stock Analysis page.